PB 1023

Drug Profile

PB 1023

Alternative Names: GLP-1-ELP-120; Glymera; PB1023

Latest Information Update: 15 Jun 2015

Price : $50

At a glance

  • Originator PhaseBio Pharmaceuticals
  • Class Antihyperglycaemics; Glucagon-like peptides; Recombinant fusion proteins
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 15 Jun 2015 Phase-II development is ongoing in the US
  • 07 Jun 2015 Preclinical trials in Type-2 diabetes mellitus (Combination therapy) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top